Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report
Cancer Chemotherapy and Pharmacology · 2023
DOI: 10.1007/s00280-023-04565-0 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Shelby Barnett und 6 weiteren Autor:innen. Beteiligte Einrichtung: Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle upon Tyne, NE2 4HH, UK. shel…. Hauptthemen laut MEDLINE: Jaundice, Chronic Idiopathic, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Experimental Cancer Medicine Centre Network, Little Princess Trust.
Abstract (Originalsprache)
Background
Dubin–Johnson syndrome is a rare benign autosomal recessive condition that causes an isolated increase of conjugated bilirubin in the serum. Impaired biliary excretion is due to mutation in the multiple drug-resistance protein 2 gene (MRP2). Case presentation We describe the case of a 4-year-old girl being treated for acute lymphoblastic leukaemia who had a history of conjugated hyperbilirubinaemia and persistently elevated bilirubin levels on initiation of chemotherapy. During treatment for leukaemia, she was diagnosed with Dubin–Johnson syndrome for the underlying condition. Following administration of vincristine at the recommended dose of 1.5 mg/m 2 , an abnormally high vincristine exposure was observed (AUC > 200 µg/L*h), approximately 3 times higher than previously reported exposures in a comparable clinical setting. Vincristine dose reductions were applied on subsequent cycles of treatment and resulted in markedly reduced drug exposures, within the normal target range.
Conclusion
This case provided a rare opportunity to assess the impact of MRP2 mutations associated with Dubin–Johnson syndrome on the pharmacokinetics of vincristine and strongly indicates that a marked dose reduction should be recommended. Clinicians should be made aware of the potential for altered drug disposition for agents such as vincristine in patients with this rare genetic condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle upon Tyne, NE2 4HH, UK. shelby.barnett@ncl.ac.uk.
- The Noah's Ark Children's Hospital for Wales, Cardiff, UK.
- Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle upon Tyne, NE2 4HH, UK.
ORCID-Profile: Gareth J Veal
Förderung
- Cancer Research UK
- Experimental Cancer Medicine Centre Network
- Little Princess Trust
Zitieren
APA
Barnett, S., Nyein, A. C., Galler, M., Jamieson, D., Davies, M., Connor, P., & Veal, G. J. (2023). Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04565-0
Vancouver
Barnett S, Nyein AC, Galler M, Jamieson D, Davies M, Connor P, et al. Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04565-0
BibTeX
@article{Barnett2023,
author = {Barnett, Shelby and Nyein, Aye Chan and Galler, Martin and Jamieson, David and Davies, Michelle and Connor, Philip and Veal, Gareth J},
title = {Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2023},
doi = {10.1007/s00280-023-04565-0}
}
EUVIMED